

MTN Closing Comments and Looking Ahead

Sharon L. Hillier, Ph.D.

Department of Obstetrics, Gynecology and
Reproductive Sciences, the University of
Pittsburgh, Pittsburgh, PA

Magee-Womens Research Institute



Many thanks.....

- Chris Rullo and Kathy McCarthy
- Daria Smolinski
- Ian McGowan, who was with us in spirit this week
- All of the speakers who made such tremendous presentations
- NIH, for joining us as presenters and for providing the support for us to have this meeting
- FHI360
- Community working group



Evaluation Forms

- Please complete these and leave them at the desk with our staff
- We do listen to your comments!



What Have We Learned Here?

- Partners in PrEP is our sister study which has demonstrated that both oral tenofovir and Truvada significantly reduce acquisition of HIV in serodiscordant couples
- Jeanne and Mike are leading the VOICE trial to its completion and orderly closeout
 - The tenofovir oral arm was found to be no more effective than placebo in our population
 - We await the next DSMB recommendation
 - The VOICE team deserves recognition for its outstanding efforts



What Have We Learned Here?

- Elizabeth Brown taught us that product adherence is dependent not only the *participant adherence* to study product, but also to *protocol adherence*
- Jonathan Stadler brought this theme forward again in his preliminary data from VOICE in which women saw themselves as “adherent”- it was just that some participants could just not get to the clinic to get their products
 - *Low protocol adherence drives low product adherence*



What Have We Learned Here?

- The site presentations have taught us about
 - the real world challenges of implementing multiple protocols at a single site
 - the amazing ingenuity brought by our sites to the implementation challenges of bringing VOICE to full enrollment on schedule
 - retention challenges, and how our colleagues in Zimbabwe and Zambia have met those challenges



Four Priorities for the MTN in 2012

- Complete VOICE, VOICE B and VOICE C
 - Complete data cleanup and prepare for the release of the data
- Launch ASPIRE in Malawi, South Africa, Zambia, Uganda and Zimbabwe in collaboration with IPM
- Expand our microbicide research in pregnant and breastfeeding women
- Launch MTN-017, our expanded safety study of the “rectal friendly” formulation of tenofovir gel



Cross-Cutting Research Priorities

- Development / optimization of biomarkers for use in clinical trials
 - Sexual exposure
 - Adherence
 - Safety
 - Efficacy
- Monitoring for ARV resistance
- Enhancing adherence through behavioral research and development of sustained delivery ARVs for prevention of HIV



MTN Awards

- Awards based on
 - data derived through the Network Evaluation Committee
 - written nominations with supporting information from lab, CORE and SCHARP and other members of the network



Outstanding CRS Pharmacies

- Verulam CRS
- Isipingo CRS



Outstanding QC Rate

- Spillhaus CRS



Outstanding Data Management

- Overport CRS



Rapid Lab Implementation

- Aurum CRS



Outstanding Retention and Clinical Management

- Kampala CRS

Thanks for coming.....

- MTN annual meeting:
February 19-22, 2012
Marriott Bethesda North
- Microbicides 2012
April 15-18, 2012
Sydney, Australia



INTERNATIONAL
MICROBICIDES
CONFERENCE
SYDNEY AUSTRALIA 15-18 APRIL 2012



www.microbicides2012.org

Scholarship and Abstracts 17 November 2011 | Early Bird Registration 31 January 2012 | Accommodation 9 March 2012 | Registration 30 March 2012